Trial Profile
The Central Nervous System Effects of Two Different HIV-Integrase Inhibitor Containing Antiretroviral Regimens.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Sep 2021
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Sponsors ViiV Healthcare
- 10 Dec 2015 Accrual to date is 45% according to United Kingdom Clinical Research Network record.
- 05 Nov 2015 Accrual to date is 36% according to United Kingdom Clinical Research Network record.
- 07 Oct 2015 Accrual to date is 31% according to United Kingdom Clinical Research Network record.